Skip to main content
group of doctors wearing lab coat and protective mask

Peripheral Interventions

Our focus

Leading devices for diagnosis and minimally-invasive treatments of peripheral vascular disease and cancer.

Nicole’s journey

Delivering meaningful innovation

Advancing the treatment of arterial disease. 

Over 200M patients around the world suffer from Peripheral Arterial Disease (PAD) with less than 1% receiving an intervention. We’ve built a strong portfolio of products to serve this market and are uniquely positioned to provide physicians and hospital systems with a full toolbox of solutions to treat patients.

Venous therapies.

 Our venous portfolio offers a category-leading breadth of venous technologies including: venous stents, endovenous chemical ablation, ultrasound assisted clot dissolution devices, mechanical thrombectomy and imaging catheters.

Next-generation interventional oncology & embolization technologies.

With targeted treatments, we can improve the lives of patients suffering from cancer and other life-altering diseases. We offer the largest interventional oncology & embolization portfolio in the industry, which includes Y-90, coils, beads, and cryoablation systems, along with access and delivery devices.

check icon

160+ products.¹

check icon

Every 16 seconds a Boston Scientific patient is treated with a Peripheral Interventions product.¹

check icon

21 active clinical trials in 2022.¹

Conditions we treat

  • Peripheral Artery Disease
  • Deep Vein Thrombosis (DVT)
  • Critical Limb Ischemia
  • Superficial Venous Disease
  • Pulmonary Embolism (PE)
  • Liver Cancer
  • Kidney Cancer


patients suffer from PAD globally.2


cases of DVT annually in the U.S. and Europe.3


diagnosed with liver cancer each year globally.4


patients suffer from CLI globally.5


causes more US deaths annually than breast cancer & AIDS combined.6

Products and solutions we offer

  • Peripheral Balloons and Stents
  • Drug-Eluting Technologies
  • Crossing Technology
  • Guidewires & Accessories
  • Venous Obstruction
  • Clot Management
  • Imaging
  • Venous Insufficiency
  • Embolization
  • Cancer Therapies
  • Tumor Ablation & Treatments
  • Access Delivery

Product Spotlights


  1. Data on file at Boston Scientific
  2. Fowkes, F, et. al., The Lancet, Volume 382, Issue 9901, 1329-1340
  3. Gerotziafas GT, et. al., Curr Opin Pulm Med. 2004; 10:356-365
  4. Cohen AT,, Thromb Haemost. 2007 Oct;98(4):756-64
  5. International Association of Cancer Registries; GLOBOCAN Database:
  6. Yost, ML, as presented at NCVH 2018
  7. Gerotziafas GT, et. al., Curr Opin Pulm Med. 2004; 10:356-365
  8. Heit JA, Abstract #910; 2005:106 (no.11) part 1 of 2, pg. 267a

*In the U.S., TheraSphere is not indicated for metastatic liver cancer treatment